Mitchell Parma, MD, discusses an analysis of survival benefit with immunotherapy in patients with NSCLC brain metastases.
Mitchell Parma, MD
Advertisement
Mitchell Parma, MD, a clinical fellow in Hematology/Oncology at the University of Texas MD Anderson Cancer Center
Articles by Mitchell Parma, MD
Advertisement
Latest Updated Articles
Dr Parma on Survival Outcomes With Immunotherapy in Patients With NSCLC Brain MetastasesPublished: June 23rd 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5